Matinas BioPharma Holdings (MTNB) Accumulated Expenses (2013 - 2026)
Matinas BioPharma Holdings (MTNB) recorded Accumulated Expenses of $504,000 in Q2 2026, down 36.6% from $795,000 a year earlier and down 27.4% from the prior quarter.
Matinas BioPharma Holdings (MTNB) Accumulated Expenses (2013 - 2026) Analysis & Trends
At the end of FY2025, Matinas BioPharma Holdings reported Accumulated Expenses of $452,000, down 75.0% from FY2024.
- Annual Accumulated Expenses has a five-year compound annual growth rate of -30.5% (FY2020 to FY2025).
- Across earlier years, Accumulated Expenses came in at $1.81 million in FY2024 (+24.7%), $1.45 million in FY2023 (-53.3%), $3.1 million in FY2022 (+8.7%) and $2.85 million in FY2021 (+2.0%).
- Quarterly Accumulated Expenses has ranged from $452,000 in Q4 2025 to $4.29 million in Q2 2022 over the past five years.
- On a year-over-year basis, Accumulated Expenses has declined for five consecutive quarters, with an average decline of 27.4% over the last eight quarters.
- Peak year-over-year performance for Accumulated Expenses in the last five years was growth of 55.4% in Q2 2022, against a decline of 75.0% in Q4 2025 at the low end.
- Per Business Quant, the preceding three quarters came in at $694,000 (Q1 2026), $452,000 (Q4 2025) and $564,000 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn |
| 10 | Matinas BioPharma Holdings | 16.34 Mn | 3.74 Mn | - |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 504,000.00 |
| Mar 31, 2026 | 694,000.00 |
| Dec 31, 2025 | 452,000.00 |
| Sep 30, 2025 | 564,000.00 |
| Jun 30, 2025 | 795,000.00 |
| Mar 31, 2025 | 1.18 Mn |
| Dec 31, 2024 | 1.81 Mn |
| Sep 30, 2024 | 1.04 Mn |
| Jun 30, 2024 | 1.44 Mn |
| Mar 31, 2024 | 839,000.00 |
| Dec 31, 2023 | 1.45 Mn |
| Sep 30, 2023 | 1.76 Mn |
| Jun 30, 2023 | 1.37 Mn |
| Mar 31, 2023 | 791,000.00 |
| Dec 31, 2022 | 3.10 Mn |
| Sep 30, 2022 | 3.70 Mn |
| Jun 30, 2022 | 4.29 Mn |
| Mar 31, 2022 | 1.84 Mn |
| Dec 31, 2021 | 2.85 Mn |
| Sep 30, 2021 | 2.89 Mn |
Matinas BioPharma Holdings Accumulated Expenses API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=accumulated-expenses&ticker=MTNB&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "accumulated-expenses", "ticker": "MTNB", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=accumulated-expenses&ticker=MTNB&period=max&api_key=YOUR_API_KEY");
const data = await res.json();